Compare Lennar Corporation (LEN) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lennar Corporation vs Merck & Co., Inc. — how do they compare? Lennar Corporation trades at $87.48 (market cap $20.57B), while Merck & Co., Inc. trades at $130.48 (market cap $323.00B). The key difference: Merck & Co., Inc. is far larger — about 15.7× Lennar Corporation's market cap, and Merck & Co., Inc. pays the higher dividend (2.6%). Which is the better fit depends on your goals.
| LEN | MRK | |
|---|---|---|
Market Cap | $20.57B | $323.00B |
Sector | Consumer Cyclical | Health |
52-Week High | $142.40 | $131.84 |
52-Week Low | $81.84 | $77.60 |
Enterprise Value | $24.45B | $369.77B |
Dividend Yield | 2.34% | 2.6% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lennar (LEN) trades at $88.18, up 3.96% in the last session, with a bullish technical signal and support at $86. The stock shows mixed fundamentals: revenue declined to $34.19B in 2025, net income fell to $2.08B, and recent EPS misses occurred, but valuation ratios like P/E of 13.82 and P/B of 0.98 suggest potential undervaluation. A dividend of $0.50 is scheduled for July 2026, while cash flow turned negative in 2025 but is projected to recover in 2026.
Outlook is cautious; analyst consensus is a 'Buy' with a $84.30 price target, but risks include housing affordability pressures and earnings volatility. Upside hinges on execution amid high mortgage rates, with institutional interest noted from CalPERS' recent share acquisition.
MRK trades at $130.90, up 1.81% today, with a bullish technical signal and strong institutional buying interest. The stock shows robust fundamentals with revenue of $65.01B in 2025 and net income of $18.25B, though a high P/E of 104.74 indicates premium valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives.
Outlook is positive with a consensus price target of $139.90, offering ~7% upside, supported by 67.57% analyst buy ratings. Risks include integration challenges from acquisitions and patent expirations, but strong cash flow and dividend payments provide stability. Investors may find value in Merck's market leadership and pipeline expansion, though valuation metrics warrant caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lennar Corporation
Lennar is the second-largest public homebuilder in the United States. The company's homebuilding operations target first-time, move-up, and active adult homebuyers mainly under the Lennar brand name. Lennar's financial-services segment provides mortgage financing and related services to its homebuyers. Miami-based Lennar is also involved in multifamily construction and has invested in numerous housing-related technology startups.
Read more on LEN →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
